Anti-TNF strategies efficiently lowered TNF-α levels with no clinical benefit [223], while Anakinra (IL-1 receptor antagonist) has only proved efficacious in a limited number of patients with macrophage activation syndrome [224]. The gene discussed is TNF; the disease is macrophage activation syndrome.